Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

Eli Lilly (NYSE:LLY) harnessed significant operational performance during the latest quarter, reporting robust sales and net ...

Click here for access. * An analyst from Morgan Stanley persists with their Overweight rating on Eli Lilly, maintaining a target price of $1124. * In a positive move, an analyst from Goldman Sachs ...

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

Brad Smith and Madison Mills take a closer look at some of today's trending tickers and top calls from Wall Street analysts ...

Eli Lilly stock (NYSE: LLY ... Notably, the average analyst price target of $1008 still suggests an upside of over 20% from the current levels. Trefis runs systematic portfolio strategies that ...

While arch rival Eli Lilly and Company ... a step function change for Lilly’s market leadership over NVO and its peers. Lilly management provided insights into the advantages of why the ...

Fintel reports that on April 28, 2025, HSBC downgraded their outlook for Eli Lilly and (BIT ... and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment ...

Our writer can see the appeal of this recently popular dividend stock from the FTSE 100 index. But will he buy it for his own ...

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...

Our writer explains why he just added to a big loser to his Stocks and Shares ISA portfolio, despite it going against one of ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...